INSTITUT PASTEUR Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging...
Tag: <span>Blood cancers</span>
Post
Target of new cancer treatment valid for breast as well as blood cancers: study
UNIVERSITY OF ALBERTA FACULTY OF MEDICINE & DENTISTRY IMAGE: UNIVERSITY OF ALBERTA ONCOLOGY RESEARCHER JOHN MACKEY (LEFT) AND CELL BIOLOGIST LUC BERTHIAUME ARE COLLABORATORS ON NEW RESEARCH SHOWING THAT PCLX-001, AN ANTI-CANCER DRUG SET TO BEGIN CLINICAL TRIALS THIS YEAR,MAY WORK AGAINST BREAST CANCER AS WELL AS LYMPHOMA CREDIT: UNIVERSITY OF ALBERTA One more piece...
Post
Immune response to COVID-19 reduced in patients with blood cancers
by The Francis Crick Institute Credit: Pixabay/CC0 Public Domain Patients with blood cancers such as leukemia vary in their immune response to COVID-19 and can struggle to clear infection for very many weeks, according to new research published in Cancer Cell. By contrast, most patients with solid tumors, even those with advanced cancer, can mount an effective and lasting...
Post
Researchers find a new therapeutic target in pancreatic cancer
by Dartmouth-Hitchcock Medical Center The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these mutations cooperate to promote cancer is unknown. A new study co-led by Steven Leach, MD, Director of Dartmouth’s and Dartmouth-Hitchcock’s...
Post
Mutation’s role in blood cancers revealed by ideal team-up
by Cold Spring Harbor Laboratory A genetic mutation that disrupts how DNA sends messages to the rest of a cell has been linked to a large number of blood cancers. Thanks to a collaboration between biologists at Cold Spring Harbor Laboratory (CSHL) and an oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), we now know...
Post
New antibody uses 1-2 punch to potentially treat blood cancers
Antibody PF-06747143 both attacks AML tumor cells and moves them from the nurturing bone marrow environment into the peripheral blood streams, where they are more vulnerable. Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood...
Post
New cell therapy offers hope of a leukaemia cure: Early trial of pioneering treatment eradicated the disease in 94% of cases
Procedure is administered during three or four hospital outpatient appointments It has shown particular promise for leukaemia and blood cancers A revolutionary cancer treatment that alters the body’s cells so they attack tumours has offered hope of a cure. The procedure is administered during three or four hospital outpatient appointments which last up to four...
Post
Researchers ID drug that blocks some blood cancers
A compound identified by Weill Cornell Medicine scientists inhibits the growth of a rare blood cancer found in people with HIV-AIDS. Their research, published May 15 in the Journal of Clinical Investigation, also demonstrates that the compound deters multiple myeloma, another type of blood malignancy. Few effective treatments are available for primary effusion lymphoma(PEL), a subtype...
- 1
- 2